PL1999136T3 - Peptydomimetyczne inhibitory PSMA, związki je zawierające i sposoby ich zastosowania - Google Patents

Peptydomimetyczne inhibitory PSMA, związki je zawierające i sposoby ich zastosowania

Info

Publication number
PL1999136T3
PL1999136T3 PL07758547T PL07758547T PL1999136T3 PL 1999136 T3 PL1999136 T3 PL 1999136T3 PL 07758547 T PL07758547 T PL 07758547T PL 07758547 T PL07758547 T PL 07758547T PL 1999136 T3 PL1999136 T3 PL 1999136T3
Authority
PL
Poland
Prior art keywords
psma
compounds
methods
peptidomimetic inhibitors
peptidomimetic
Prior art date
Application number
PL07758547T
Other languages
English (en)
Inventor
Cliff Berkman
Original Assignee
Cancer Targeted Tech Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cancer Targeted Tech Llc filed Critical Cancer Targeted Tech Llc
Publication of PL1999136T3 publication Critical patent/PL1999136T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/40—Esters thereof
    • C07F9/4003—Esters thereof the acid moiety containing a substituent or a structure which is considered as characteristic
    • C07F9/4006—Esters of acyclic acids which can have further substituents on alkyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • C07F9/091—Esters of phosphoric acids with hydroxyalkyl compounds with further substituents on alkyl
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/22—Amides of acids of phosphorus
    • C07F9/222—Amides of phosphoric acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/22—Amides of acids of phosphorus
    • C07F9/24—Esteramides
    • C07F9/2404—Esteramides the ester moiety containing a substituent or a structure which is considered as characteristic
    • C07F9/2408—Esteramides the ester moiety containing a substituent or a structure which is considered as characteristic of hydroxyalkyl compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/22—Amides of acids of phosphorus
    • C07F9/24—Esteramides
    • C07F9/2404—Esteramides the ester moiety containing a substituent or a structure which is considered as characteristic
    • C07F9/2416—Esteramides the ester moiety containing a substituent or a structure which is considered as characteristic of cycloaliphatic alcohols
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/22—Amides of acids of phosphorus
    • C07F9/24—Esteramides
    • C07F9/2404—Esteramides the ester moiety containing a substituent or a structure which is considered as characteristic
    • C07F9/2429—Esteramides the ester moiety containing a substituent or a structure which is considered as characteristic of arylalkanols
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/22—Amides of acids of phosphorus
    • C07F9/24—Esteramides
    • C07F9/2454—Esteramides the amide moiety containing a substituent or a structure which is considered as characteristic
    • C07F9/2458—Esteramides the amide moiety containing a substituent or a structure which is considered as characteristic of aliphatic amines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/655—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms
    • C07F9/6552—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a six-membered ring
    • C07F9/65522—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a six-membered ring condensed with carbocyclic rings or carbocyclic ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pyrane Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Steroid Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
PL07758547T 2006-03-14 2007-03-14 Peptydomimetyczne inhibitory PSMA, związki je zawierające i sposoby ich zastosowania PL1999136T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US78221106P 2006-03-14 2006-03-14
PCT/US2007/064002 WO2007106869A1 (en) 2006-03-14 2007-03-14 Peptidomimetic inhibitors of psma,compounds comprising them, and methods of use
EP07758547A EP1999136B1 (en) 2006-03-14 2007-03-14 Peptidomimetic inhibitors of psma,compounds comprising them, and methods of use

Publications (1)

Publication Number Publication Date
PL1999136T3 true PL1999136T3 (pl) 2013-03-29

Family

ID=38229662

Family Applications (1)

Application Number Title Priority Date Filing Date
PL07758547T PL1999136T3 (pl) 2006-03-14 2007-03-14 Peptydomimetyczne inhibitory PSMA, związki je zawierające i sposoby ich zastosowania

Country Status (9)

Country Link
US (3) US7696185B2 (pl)
EP (1) EP1999136B1 (pl)
JP (1) JP2009532338A (pl)
CN (1) CN101443340B (pl)
AU (1) AU2007226542B2 (pl)
CA (1) CA2645809C (pl)
ES (1) ES2397973T3 (pl)
PL (1) PL1999136T3 (pl)
WO (1) WO2007106869A1 (pl)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009002529A2 (en) 2007-06-26 2008-12-31 The Johns Hopkins University Labeled inhibitors of prostate specific membrane antigen (psma), biological evaluation, and use as imaging agents
CN104873982A (zh) 2007-08-17 2015-09-02 普渡研究基金会 Psma结合配体-接头缀合物及其使用方法
WO2010045598A2 (en) * 2008-10-17 2010-04-22 Purdue Research Foundation Psma binding ligand-linker conjugates and methods for using
WO2010149666A1 (en) * 2009-06-22 2010-12-29 Medexis S.A. Methods for treating neoplasia
EP2338892A1 (en) 2009-12-18 2011-06-29 Bayer Schering Pharma Aktiengesellschaft Prostate specific membrane antigen inhibitors
US9951324B2 (en) 2010-02-25 2018-04-24 Purdue Research Foundation PSMA binding ligand-linker conjugates and methods for using
WO2011106639A1 (en) * 2010-02-25 2011-09-01 Purdue Research Foundation Psma binding ligand-linker conjugates and methods for using
JP5657902B2 (ja) * 2010-03-17 2015-01-21 株式会社コスモステクニカルセンター ポリオキシアルキレンステロールエーテル誘導体及び／又はポリオキシアルキレンスタノールエーテル誘導体、及びそれを含有する外用剤組成物
WO2012064914A2 (en) * 2010-11-12 2012-05-18 Washington State University Research Foundation Peptidomimetic inhibitors of psma
CN103930432B (zh) * 2011-06-15 2017-06-23 癌靶技术有限责任公司 螯合的psma抑制剂
WO2013173583A1 (en) 2012-05-16 2013-11-21 Cancer Targeted Technology, Llc Psma inhibitors
EP3858341A1 (en) 2012-11-15 2021-08-04 Endocyte, Inc. Psma ligand-containing conjugates for the treatment of prostate cancer
EP2970345B1 (en) * 2013-03-15 2019-06-19 Cancer Targeted Technology LLC 18f-labeled psma-targeted pet imaging agents
EP2842578B1 (en) * 2013-08-27 2018-06-27 GILUPI GmbH Diagnostic device for the detection of biomarkers
KR101947053B1 (ko) 2013-10-18 2019-02-12 도이체스 크렙스포르슝스첸트룸 전립선 특이적 막 항원（ｐｓｍａ）의 표지된 억제제, 조영제로서의 이의 용도 및 전립선암 치료용 약제
WO2016028700A1 (en) * 2014-08-18 2016-02-25 Washington State University Tunable ph-sensitive linker for controlled drug release
US10188759B2 (en) 2015-01-07 2019-01-29 Endocyte, Inc. Conjugates for imaging
US9808538B2 (en) * 2015-09-09 2017-11-07 On Target Laboratories, LLC PSMA-targeted NIR dyes and their uses
CA3030907A1 (en) 2016-08-10 2018-02-15 Cancer Targeted Technology Llc Chelated psma inhibitors
WO2021046233A1 (en) 2019-09-03 2021-03-11 Cancer Targeted Technology Llc Chelate-containing psma inhibitors
CN113117100B (zh) * 2019-12-31 2024-03-01 广东精观生物医药科技有限公司 一种靶向psma的荧光分子探针及其制备方法和应用
CN111675747B (zh) * 2020-07-30 2021-04-27 中国医学科学院医药生物技术研究所 抗肿瘤药物和用途

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US782211A (en) 1904-05-23 1905-02-07 George W Sturgis Vending-wagon.
KR20000016750A (ko) * 1996-06-17 2000-03-25 토마스 씨. 서 Naaladase 억제를 이용한 암의 치료방법.
AU4322102A (en) * 2000-11-20 2002-06-18 Eastern Virginia Med School Methods and devices for the quantitative detection of prostate specific membraneantigen and other prostatic markers
MXPA03007037A (es) * 2001-02-07 2003-11-18 Beth Israel Hospital Ligandos del antigeno de membrana especifico de prostata (amep) y usos relacionados del mismo.
KR20040077889A (ko) * 2002-01-28 2004-09-07 메다렉스, 인코포레이티드 전립선 특이적 막 항원 (ｐｓｍａ)에 대한 인간모노클로날 항체

Also Published As

Publication number Publication date
CN101443340A (zh) 2009-05-27
EP1999136A1 (en) 2008-12-10
AU2007226542A1 (en) 2007-09-20
WO2007106869A1 (en) 2007-09-20
CA2645809A1 (en) 2007-09-20
CA2645809C (en) 2015-05-26
JP2009532338A (ja) 2009-09-10
US8293725B2 (en) 2012-10-23
AU2007226542B2 (en) 2013-08-22
US20070219165A1 (en) 2007-09-20
ES2397973T3 (es) 2013-03-12
US20100183517A1 (en) 2010-07-22
EP1999136B1 (en) 2012-10-24
USRE42275E1 (en) 2011-04-05
US7696185B2 (en) 2010-04-13
CN101443340B (zh) 2013-12-04

Similar Documents

Publication Publication Date Title
PL1999136T3 (pl) Peptydomimetyczne inhibitory PSMA, związki je zawierające i sposoby ich zastosowania
HUS2200052I1 (hu) Imidazotriazinok és imidazopirimidinek mint kinázgátlók
HK1225722A1 (zh) 激酶活性抑製劑
PL1940839T3 (pl) Pirydopirymidynonowe inhibitory PI3Kalfa
ZA200802585B (en) Pyridopyrimidinone inhibitors of Pl3Kα
EP2142287A4 (en) INHIBITORS OF LYSINE-SPECIFIC DEM ETHYLASE
EP2200977A4 (en) F1F0-ATPASE INHIBITOR AND ASSOCIATED METHODS
EP2076128A4 (en) PROTEIN CHINESE INHIBITOR AND ITS USE METHOD
IL205205A0 (en) Beta - lactamase inhibitors
HK1144070A1 (zh) 肽脫甲酰基酶抑制劑
EP2084139A4 (en) OXAZOLIDINIUM COMPOUNDS AND USE AS HYDRATINE HIBITORS
HK1137756A1 (en) Substituted dihydropyrazolones and use thereof as hif-prolyl-4 -hydroxylase inhibitors hif--4-
ZA201003420B (en) Protein kinase inhibitors and use thereof
IL207415A0 (en) Protein kinase inhibitors and use thereof
IL197981A0 (en) Kinase inhibitors
GB0504209D0 (en) New use of PDE7 inhibitors
SI1940839T1 (sl) Piridopirimidin PI3K alfa inhibitorji
GB0621107D0 (en) Inhibitors of phosphodiesterase-4
GB0625381D0 (en) Novel inhibitors of flaviridae
GB0621719D0 (en) Ikk- serine-threonine protein kinase inhibitors